Kornimate/medical-research-clean huggingface dataset:
post market study using the elite iq device

Conditions: Hair Removal; Pseudo Folliculitis Barbae; Benign Vascular Lesion; Pigmented Lesions

Summary: this is a prospective, open label, single-center clinical study to collect safety and efficacy data on the elite iq workstation. the intended use of the elite iq device used in this study is for the treatment of hair removal, pseudo folliculitis barbae, and benign vascular and pigmented lesions.

up to 20 subjects will be enrolled at up to 1 study center. subjects will attend a screening/pretreatment visit which may be performed on the same day as the treatment visit. subjects may receive up to 5 treatments on multiple areas of the body such as, but not limited to, the face, legs, and arms. all subjects will be required to return a follow-up visit at 30 - 90 days after the final treatment in each treatment area.

Eligibility criteria:
inclusion criteria: * a healthy male or female 18 years of age or older. * understands and accepts obligation not to receive any other procedures on the treatment area through the length of the study. * understands and accepts the obligation and is logistically able to be present for all visits. * is willing to comply with all requirements of the study and sign the informed consent document. exclusion criteria: * the subject is hypersensitive to light in the near infrared wavelength region * the subject has sun-damaged skin (treatment contraindicated with alex laser only) * the subject had recent unprotected sun exposure (for alex laser within four weeks of treatment; for nd:yag laser within one week of treatment), including the use of tanning beds or tanning products, such as creams, lotions and sprays * the subject is taking medication which is known to increase sensitivity to sunlight * the subject has seizure disorders triggered by light * the subject is taking anticoagulants * the subject is taking or have taken oral isotretinoin, such as accutane®, within the last six months * the subject is taking medication that alters the wound-healing response * the subject has a history of healing problems or history of keloid formation * the subject has an active localized or systemic infection, or an open wound in area being treated * the subject has a significant systemic illness or an illness localized in area being treated * the subject has a history of skin cancer or suspicious lesions * the subject has an autoimmune disease * the subject is receiving or have received gold therapy * the subject is currently enrolled in an investigational drug or device trial, or has received an investigational drug or been treated with an investigational device within in the area to be treated 6 months to entering this study. * the subject has any condition or is in a situation which in the investigators opinion may put the subject at significant risk, may confound study results or may interfere significantly with the subject's participation.
peripheral artery disease in patients with stable coronary artery disease in general practice: prevalence, management and clinical outcomes.

Conditions: Peripheral Artery Disease

Summary: patients with lower extremity peripheral artery disease (pad) are at risk of developing major adverse limb events and have a similar cardiovascular (cv) morbidity and mortality to those with coronary artery disease (cad) with which is associated in most cases with a more severe prognosis. because of higher risk conferred by concomitant pad an early diagnosis is recommended in subjects with cad. pad can be diagnosed relatively easily and noninvasively with the ankle-brachial index (abi) measure. an abi ≤0.9 is an indicator of the presence of lower extremity pad, indicating athero-occlusive arterial disease while \>1.3/1.4 indicates an incompressible ankle arteries. however, abi is not routinely applied in the clinical practice. data on prevalence of pad are scanty and in patients with stable cad are lacking. the under-diagnosis of pad may be a barrier to the use of treatments to improve prognosis. the primary aim of this study is to assess the coexistence of pad in subjects with stable cad and to evaluate the management and the prognosis of these patients in primary care at 12-month after the inclusion in the study.

national, multicentre, observational, prospective study. this study will be carried out with the collaboration with study center for primary care and with the italian society of angiology and vascular medicine (siapav). the eligible patients with stable cad will be called by general practitioners (gps). for all patients who agree to participate in the study and sign the consent, two visits will be done at baseline and after 12 months. at baseline will be collected information on socio-demographic and anthropometric data, blood pressure, heart rate, cv risk factors, medical history, lifestyle habits, pad stage (for patient with abnormal abi) and pharmacological therapy. abi measurement will be done using an automatic simple device. in case of abnormal abi value, a siapav vascular specialist, at gp's office, will confirm it using the standard manual continuous wave (cw) doppler. at follow-up visit the following information will be collected the: referral to vascular specialist (if requested, at discretion of the gp), relevant change in pharmacological therapy, major cv events and progression of pad, limb and coronary artery revascularizations, amputations, major bleeding, and death.

Eligibility criteria:
inclusion criteria: * patients of both sexes with a diagnosis of stable cad as follows: acute myocardial infarction or percutaneous coronary revascularization or coronary artery bypass graft surgery occured at least 12 months before entering the study or chronic stable angina. exclusion criteria: * mental illness limiting the capacity of self-care or any condition limiting seriously the life expectancy less than 12 months.

Keywords: peripheral artery disease coronary artery disease general practice ankle-brachial index (abi)
posturing effects on perception of time and perceptions of the provider-patient interaction in the emergency department

Conditions: Healthy

Summary: study objective: * to examine the perceptions of time spent at the bedside; perceptions of bedside manner; and patient perceptions of the provider-patient interaction offered by emergency providers when they sit versus when they stand during the initial evaluation. this project is clinically relevant research different from prior emergency department (ed) satisfaction studies since this study will contribute information about factors that could increase patient satisfaction with his/her provider in the ed setting. this research may guide specific guidelines for quality improvement efforts. the investigators hypothesize that patients will perceive that the emergency providers are at the bedside longer, demonstrate better bedside manner, and have better provider-patient interactions when they sit versus when they stand. additionally, the investigators hypothesize that providers who sit will perceive that they are at the bedside longer than those who stand for the same period of time. methods: a convenience sample of adult patients will complete a 5-item questionnaire concerning the perceived time spent with the emergency provider and the qualities of the provider-patient interaction. emergency providers will be randomly assigned to either sit or stand during the initial evaluation. the providers will complete a 4-item questionnaire. these data will be compared to the actual time spent in the evaluation, measured in seconds, using a stopwatch. these data, combined with demographic data obtained from the patient chart, will be analyzed to examine whether there are statistically significant differences in patient perceptions and satisfaction.


Eligibility criteria:
inclusion criteria: * the subject population represents a convenience sample of patients 18 years and older who give consent. * all english speaking individuals with adequate health status and cognitive function to communicate answers to the investigator. * there are no foreseen reasons to exclude pregnant women as they are not likely to be vulnerable in this study. exclusion criteria: * unstable patients and patients seen in the critical care area will be excluded from study.

Keywords: age 18 years or older no cognitive impairment or altered mental status stable no aphasia english-speaking
cystine capacity clinical study (cyscap)

Conditions: Cystinuria

Summary: the purpose of this study is to determine whether urinary cystine capacity, an assay used to measure the amount of cystine in the urine, can be used to predict stone recurrence in patients with cystinuria.

cystinuria is a rare genetic cause of kidney stones that leads to significant morbidity due to the recurrent nature of the disease. despite recent advancements in knowledge about cystinuria, such as the discovery of the genetic defects that cause the disease, there have been very few studies of clinical determinants of recurrent stone formation. an optimal method of measuring cystine solubility in the urine has been lacking, and therefore response to pharmacologic and dietary therapy is often not known. recently, a new assay to measure the amount of cystine in the urine was developed called cystine capacity, or cyscap. it is an assay that adds a pre-formed amount of cystine crystals to urine and measures the amount of cystine the urine can take up from the solid phase (in undersaturated urine) or gives up to solid phase (in supersaturated urine). this study seeks to examine how well this measure of urinary cystine predicts stone occurrence, with the ultimate goal of helping to guide therapy and preventing kidney stones in cystinurics. this is an observational study over 3 years. subjects who are enrolled in the study will perform semi-annual 24-hour urine collections. they will undergo imaging of the kidneys every 6 months to monitor kidney stone formation or growth, in order to correlate urinary parameters with clinical events. the study will examine how well the urinary cystine capacity predicts stone formation.

Eligibility criteria:
inclusion criteria: * patients with a confirmed laboratory diagnosis of cystinuria will be included in this study. there will be no age barrier to inclusion, but included patients must be able to reliably collect urine for 24 hours. men and women will be recruited equally and there are no restrictions for racial or ethnic origin in this study. * patient enrollment will require signing of an informed consent document approved by the lenox hill irb. * for children 8-18 years of age, signing an assent to participate will also be required. exclusion criteria: * patients will be excluded if they cannot sign consent or assent. * furthermore if the patient cannot reliably collect urine for 24 hours or adhere to study follow up visit requirements.

Keywords: renal aminoaciduria cystinuria d-penicillamine renal tubular transport inborn errors tiopronin urolithiasis
asap study - hospital-based brief intervention for alcohol problems

Conditions: Alcohol Dependence; Alcohol Consumption

Summary: the objective of this project was to test whether screening and brief intervention for unhealthy alcohol use leads to improved alcohol-related outcomes (such as alcohol consumption and linkage to alcohol assistance) and is cost-effective.

in this study the effectiveness and cost-effectiveness of brief intervention for unhealthy alcohol use in a diverse group of hospitalized medical patients was tested. we conducted a randomized trial of medical inpatients with the whole spectrum of alcohol problems from risky use through dependence. subjects in one group received standard care; subjects in the second group received a brief motivational intervention tailored to the severity of his or her alcohol problem. primary outcomes are alcohol consumption and linkage to alcohol treatment. additional outcomes include health-related quality of life, health care utilization, alcohol problems, and readiness to change. costs, and clinical outcomes measured in quality-adjusted life years, a standard metric that allows comparison to other chronic illnesses, will be compared in a cost-effectiveness analysis.

Eligibility criteria:
inclusion criteria: * 18 years of age or older * fluent in english or spanish * consume risky amounts of alcohol * provide 2 contacts to assist with follow-up * have no plans to move from the local area within a year of screening * score \>21 on mini-mental state examination (no serious cognitive impairment)

Keywords: alcohol alcohol abuse alcohol dependence utilization alcohol consumption unhealthy alcohol use hospitalization screening brief intervention motivational interviewing randomized trial effectiveness unhealthy alcohol use (risky alcohol consumption amounts, problem alcohol use, hazardous alcohol use, alcohol abuse and alcohol dependence)
the development and validation of empower-up: a generic questionnaire for measuring empowerment in patient-provider relationships

Conditions: Cancer; Diabetes; Mental Disorder

Summary: empowerment is widely acknowledged as an important approach in long-term care. the concept relates to the individual's ability to manage their own life and make rational decisions. despite good intentions of working empowerment-based, research has shown that it can be difficult to realize and achieve in everyday practice within the healthcare system. to this date, no measurement instrument (questionnaire) exists that evaluate people's perceptions of whether their relationship with a healthcare provider promotes their empowerment process. the empower-up questionnaire was therefore developed to provide such a measure. the empower-up study aims to finalize the development process of the questionnaire and to test whether it is a valid and reliable measure. people at the age of 18 years or above can participate if they have ever been diagnosed with a type of cancer, diabetes, or a mental illness and because of that diagnosis have been in contact with the healthcare system within the past six months. the study is conducted online and requires participants to fill out an online questionnaire on a single occasion. participation is expected to take no more than 10-15 minutes. by participating, people may experience an increased awareness as to the nature of their interactions with healthcare providers. for some, this awareness may be beneficial and may alone enable them to ask for better care, while others may experience it as a burden if they are not able to seek better care. by participating, people are helping to ensure that empower-up will be a good questionnaire that may help raise awareness of the quality of relationships within the healthcare system and in term lead to better care. the study is led by a team of researchers at the danish university hospital rigshospitalet and the university of copenhagen, denmark. the uk lead of the study is located at king's college london, uk. the australian lead of the study is located at deakin university, melbourne, australia. this study is financially supported by the novo nordisk foundation's steno collaborative grant and by the trygfonden foundation (denmark)


Eligibility criteria:
inclusion criteria: * ever diagnosed with cancer, diabetes, or a mental disorder and have had an interaction with a healthcare provider concerning their cancer/diabetes/mental disorder diagnosis within the past six months (relating to e.g. treatment or follow-up consultations) exclusion criteria: * unable to read and understand danish (for danish participants) or english (for uk and australian participants)
safety and pharmacokinetics of intravenous and oral apx001 in patients with acute myeloid leukemia (aml) and neutropenia

Conditions: Acute Myeloid Leukemia

Summary: an open-label, multi-center, phase ib study to determine the safety and pharmacokinetics of intravenous and oral apx001 in patients undergoing chemotherapy for acute myeloid leukemia with neutropenia. a total of 20 patients will be enrolled in this study. 10 patients in cohort i, intravenous drug dosing and 10 patients will be enrolled in cohort ii, oral drug dosing. all patients will receive chemotherapy for their aml according to local clinical standard of care as well as antifungal prophylaxis. apx001 will be administered for 14 consecutive days, beginning on study day 3 after onset of chemotherapy


Eligibility criteria:
key inclusion criteria: * provision of written consent * ages 18-75 inclusive, male or female * diagnosis of acute myeloid leukemia * patients entering first induction treatment chemotherapy * expected to be neutropenic (\ /= 10 days key exclusion criteria: * patients who received systemic antifungal therapy for proven or probable fungal infections within the last 12 months * current fever (\> 38 degrees celsius) * concomitant use of rifampin, rifabutin, ergot alkaloids, terfenadine, astemizole, cisapride, pimozide, quinidine, long acting barbiturates, neostigmine and carbamazepine
epidemiology of viral hepatitis among subjects in precarious

Conditions: Social Insecurity

Summary: social insecurity is a significant cost in human terms (health and societal), it defines evil and can be identified as difficulties accessing health and especially water. we chose to take stock of these populations defined by difficulties accessing water as precarious setting. subjects homeless population fall into this by accident of life, a life "homeless" or migrant subjects often illegally having only transitory access (associative or charitable structures host) the conditions precarious sanitation including drinking water or toilet. populations of slums in the same conditions or the presence rationed water (one tap for 150 people) restricts hygiene.

social insecurity is a significant cost in human terms (health and societal), it defines evil and can be identified as difficulties accessing health and especially water. we chose to take stock of these populations defined by difficulties accessing water as precarious setting. subjects homeless population fall into this by accident of life, a life "homeless" or migrant subjects often illegally having only transitory access (associative or charitable structures host) the conditions precarious sanitation including drinking water or toilet. populations of slums in the same conditions or the presence rationed water (one tap for 150 people) restricts hygiene. the sampling system as part of a consultation in routine care (will be in dbs (blotter) only alternative to invasive venous sample and requiring heavier care facility. the capillary sampling on filter will also detect a marker of malnutrition . thus in live in large social precariousness adult this study should show which interventions in public health and management proposals are most appropriate for this population.

Eligibility criteria:
inclusion criteria: * population homeless (sdf) * population living in slums. exclusion criteria: * pregnant or lactating women
advanced practice provider intervention study to promote wellness

Conditions: Job Stress; Professional Burnout

Summary: this exploratory pilot study is designed as interventional study to examine the efficacy of a wellness initiative that involves use of a licensed clinical professional counselor (lcpc) to assist in the development of diverse coping strategies such as management of stressors, self-care, time management, and any other goals, problems or concerns that apps would like assistance with during the intervention period.

the purpose of this study is to evaluate an educational professional wellness program designed to assist professional clinicians in developing self-awareness and self-care choices as a means to improve engagement and resilience and to avoid/reduce burnout.

Eligibility criteria:
inclusion criteria: * employment within non-profit health care setting as a health care professional * working at least 50% of time in direct patient care * availability and interest in initial and follow-up wellness visits exclusion criteria: * actively participating in formalized counseling sessions through other services at time of recruitment into the study

Keywords: resilience burnout work engagement
prediction of benefit from adjuvant chemotherapy for pt1n1 gastric cancer

Conditions: Gastric Cancer

Summary: to conduct a retrospective study to prove a hypothesis of "adjuvant chemotherapy provides survival benefit for patients of ctx-benefit group in gastric cancer of pt1n1, especially in high-risk group". this study is a pilot study and the result will be used as a reference for the upcoming prospective randomized controlled trial for same issue including estimating sample size. two high-volume hospitals (yonsei university severance hospital and samsung hospital) will participant this pilot study. ffpe sample blocks and clinical information pertaining to the patients who satisfied with selection criteria will be collected from two institutions. the primary end point of this study is disease-free survival (dfs) that is defined as the time from surgery to death or gastric cancer recurrence whichever occurred first; and overall survival (os) that is defined as time from surgery to death by any causes. clinical information such as age, sex, histology, lauren classification, depth of invasion, number of retrieved and metastatic lymph nodes, sizes of tumor, location of tumor, gross type, lympho-vascular invasion, received chemotherapy or not will be centralized. one or 2 of 3mm core of tumor will be punched from ffpe and it will be delivered through eppendorf tube to laboratory (novomics co. ltd., seoul, korea). rna will be extracted from the tissue and the pattern of rna expression will be evaluated and each sample will be categorized into three risk group (high, intermediate, low risk group) and two predictive group (ctx-benefit and no-benefit group) by gmp-grade nprofiler 1tm stomach cancer assay kit (novomics co. ltd., seoul, korea). both clinical information and classification will be delivered to independent statisticians who are responsible to conduct statistical analyses.


Eligibility criteria:
inclusion criteria: 1. pathologically confirmed gastric adenocarcinoma 2. patients who received r0 resection with curative intent surgery 3. pt1 (mucosa/submucosa) n1(one or two metastatic lymph nodes) m0 4. patients received surgery with lymph node dissection of d1 + or more 5. number of retrieved lymph nodes \>15 6. formalin-fixed paraffin-embedded cancer tissues are available 7. adults over 19 years exclusion criteria: 1. patients received pre-operative chemotherapy or radiotherapy 2. cancer in remnant stomach (history of gastrectomy) 3. in hospital mortality or died within 30 days after surgery 4. ffpe is not available

Keywords: gastric cancer biomarker chemotherapy precise medicine
conventional sils vs harmonic scalpel sils

Conditions: Gallbladde Stones

Summary: single incision laparoscopic cholecystectomy is gaining widespread acceptance. there are some obstacles making this procedure more complex than conventional laparoscopic cholecystectomy. the use of harmonic scalpel may aid in solving some of these issues that may allow simplification of the technique. the investigators will compare the ordinary method of single incision laparoscopic cholecystectomy versus harmonic scalpel single incision laparoscopic cholecystectomy.


Eligibility criteria:
inclusion criteria: * patients with symptomatic gallbladder stones exclusion criteria: * acute cholecystitis cbd stones contraindications for laparoscopy